» Articles » PMID: 17610571

AAV-mediated Delivery of BDNF Augments Neurogenesis in the Normal and Quinolinic Acid-lesioned Adult Rat Brain

Overview
Journal Eur J Neurosci
Specialty Neurology
Date 2007 Jul 6
PMID 17610571
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Brain-derived neurotrophic factor (BDNF) plays a major role in regulating the survival and fate of progenitor cells in the adult brain. In order to extend previous observations in the normal adult brain and advance our knowledge regarding the effect of BDNF on neurogenesis in the injured brain, this study directly compared the effect of BDNF on basal and injury-induced neurogenesis in relation to progenitor cell distribution and levels of neuronal differentiation and survival. BDNF was overexpressed in the subventricular zone (SVZ) via recombinant adeno-associated virus (AAV(1/2)) delivery, and newly generated cells were identified using bromodeoxyuridine (BrdU) labelling. Selective striatal cell loss was induced in a subgroup of rats by unilateral striatal injection of quinolinic acid (QA) 21 days after AAV(1/2) injection. In the normal brain, BDNF overexpression significantly increased BrdU-positive cell numbers in the rostral migratory stream, indicating enhanced progenitor cell migration. Following QA lesioning, we observed a reduction in BrdU immunoreactivity in the SVZ. Overexpression of BDNF restored BrdU-positive cell numbers in the QA-lesioned SVZ to that observed in the normal brain. Most significantly, BDNF enhanced the recruitment of progenitor cells to the QA-lesioned striatum and promoted neuronal differentiation in both the normal and QA-lesioned striatum. Our findings indicate that BDNF augments the recruitment, neuronal differentiation and survival of progenitor cells in both neurogenic and non-neurogenic regions of the normal or QA-lesioned brain. Enhanced expression of BDNF may therefore be a viable strategy for augmenting neurogenesis from endogenous progenitor cells.

Citing Articles

Reprogrammed human lateral ganglionic eminence precursors generate striatal neurons and restore motor function in a rat model of Huntington's disease.

McCaughey-Chapman A, Burgers A, Combrinck C, Marriott L, Gordon D, Connor B Stem Cell Res Ther. 2024; 15(1):448.

PMID: 39578834 PMC: 11583420. DOI: 10.1186/s13287-024-04057-9.


Comprehensive characterization of the neurogenic and neuroprotective action of a novel TrkB agonist using mouse and human stem cell models of Alzheimer's disease.

Charou D, Rogdakis T, Latorrata A, Valcarcel M, Papadogiannis V, Athanasiou C Stem Cell Res Ther. 2024; 15(1):200.

PMID: 38971770 PMC: 11227723. DOI: 10.1186/s13287-024-03818-w.


Emerging Pro-neurogenic Therapeutic Strategies for Neurodegenerative Diseases: A Review of Pre-clinical and Clinical Research.

Vassal M, Martins F, Monteiro B, Tambaro S, Martinez-Murillo R, Rebelo S Mol Neurobiol. 2024; 62(1):46-76.

PMID: 38816676 PMC: 11711580. DOI: 10.1007/s12035-024-04246-w.


Development of Pleiotropic TrkB and 5-HT Receptor Ligands as Neuroprotective Agents.

Antonijevic M, Charou D, Davis A, Curel T, Valcarcel M, Ramos I Molecules. 2024; 29(2).

PMID: 38276593 PMC: 10819171. DOI: 10.3390/molecules29020515.


Differential contribution of TrkB and p75 to BDNF-dependent self-renewal, proliferation, and differentiation of adult neural stem cells.

Lozano-Urena A, Frade J Front Mol Neurosci. 2024; 16:1271820.

PMID: 38188197 PMC: 10770873. DOI: 10.3389/fnmol.2023.1271820.